Cencora — Aug 5, 2026 release

In the quarter, the Company opportunistically repurchased $1 billion of shares, which is the amount that the Company previously expected to complete by the end of calendar 2026. 2026 Guidance (1) Fiscal 2025 Actuals Revenue 4% to 6% growth $321.3B U.S. Healthcare Solutions Segment (2) 4% to 6% growth $285.0B International Healthcare Solutions Segment (2)(3) ~8% growth $28.3B Other (2) ~6% growth $8.2B Adjusted operating income 13% to 14% growth $4.2B U.S. Healthcare Solutions Segment (2) 14.5% to 15.5% growth $3.3B International Healthcare Solutions Segment (2)(3) ~9% growth $588M Other (2) ~10% growth $352M Adjusted diluted earnings per share $17.75 to $17.95 $16.00 Net interest expense ~$490M $292M Adjusted effective tax rate ~20% 20.6% Diluted weighted average shares outstanding ~194M 195.2M Adjusted free cash flow ~$3.0B $3.0B Capital expenditures ~$900M $668M (1) Bolded figures indicate updates to guidance metrics. (2) For further detail on fiscal 2025 revised reportable segment information, please refer to Exhibit 99.2 to the Company’s Current Report on Form 8-K dated November 5, 2025. 4 (3) As reported guidance. For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation for investors posted on the Company’s website at investor.cencora.com. Dividend Declaration     The Company’s Board of Directors declared a quarterly cash dividend of $0.